Neurocrine Biosciences, Inc. (NBIX)
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic
$128.17
+0.10%
Mkt Cap $13.07B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 11, 2026 | $790.50M | $805.50M | +1.90% | $1.80 | $1.88 | +4.44% | — | — |
| Q4 2025 Oct 28, 2025 | $806.80M | $794.90M | -1.48% | $1.58 | $2.04 | +29.11% | — | — |
| Q3 2025 Jul 30, 2025 | $746.41M | $687.50M | -7.89% | $0.98 | $1.06 | +8.16% | — | — |
| Q2 2025 May 5, 2025 | $559.63M | $572.60M | +2.32% | $0.54 | $0.08 | -85.05% | — | — |
| Q1 2025 Feb 6, 2025 | $629.44M | $627.70M | -0.28% | $1.62 | $1.00 | -38.27% | — | — |
| Q4 2024 Oct 30, 2024 | $600.64M | $622.10M | +3.57% | $1.51 | $1.24 | -17.88% | — | — |
| Q3 2024 Aug 1, 2024 | $545.94M | $590.20M | +8.11% | $1.05 | $0.63 | -40.00% | — | — |
| Q2 2024 May 1, 2024 | $512.40M | $515.30M | +0.57% | $1.01 | $0.42 | -58.42% | — | — |
| Q1 2024 Feb 7, 2024 | $519.12M | $515.20M | -0.76% | $1.15 | $1.44 | +25.22% | — | — |
| Q4 2023 Oct 31, 2023 | $468.15M | $498.80M | +6.55% | $0.97 | $0.82 | -15.46% | — | — |
| Q3 2023 Aug 1, 2023 | $447.31M | $452.70M | +1.20% | $0.78 | $0.95 | +21.79% | — | — |
| Q2 2023 May 3, 2023 | $409.26M | $420.40M | +2.72% | $0.26 | -$0.79 | -403.85% | — | — |
| Q1 2023 Feb 6, 2023 | $408.87M | $412.00M | +0.77% | $1.16 | $0.88 | -24.14% | — | — |
| Q4 2022 Nov 1, 2022 | $377.00M | $387.90M | +2.89% | $0.79 | $0.69 | -12.66% | — | — |
| Q3 2022 Aug 4, 2022 | $342.33M | $378.20M | +10.48% | $0.56 | -$0.18 | -132.14% | — | — |
| Q2 2022 May 4, 2022 | $304.07M | $310.60M | +2.15% | $0.35 | $0.14 | -60.00% | — | — |
| Q1 2022 Feb 11, 2022 | $317.49M | $312.00M | -1.73% | $0.61 | -$0.08 | -113.11% | — | — |
| Q4 2021 Nov 1, 2021 | $296.58M | $296.00M | -0.20% | $0.51 | $0.23 | -54.90% | — | — |
| Q3 2021 Aug 3, 2021 | $288.90M | $288.90M | +0.00% | $0.48 | $0.43 | -10.42% | — | — |
| Q2 2021 May 5, 2021 | $253.22M | $236.60M | -6.56% | $0.51 | $0.33 | -35.29% | — | — |